COGNITIVE PHARMACEUTICALS
Cognitive develops drug leads as a virtual company. Cognitive Pharmaceuticals was formed by Messer, Hoss, and others in 2001, based on a proprietary platform technology developed at the University of Toledo, College of Pharmacy. Cognitive Pharmaceuticals has completed a merger with Mithridion.
COGNITIVE PHARMACEUTICALS
Industry:
Biotechnology Health Care Life Science Pharmaceutical
Founded:
2001-01-01
Status:
Active
Similar Organizations
Ayerst Pharmaceuticals
Ayerst Pharmaceuticals was added in 2013.
Berk Pharmaceutical
Berk Pharmaceutical is a Pharmaceuticals company.
Biopsy Sciences
Biopsy Sciences develops breast biopsy site markers.
Maneesh Pharmaceuticals
Maneesh Pharmaceuticals is a pharmaceutical company.
Nostix
Nostix LLC develops a non-invasive glucose monitor.
More informations about "Cognitive Pharmaceuticals"
Cognitive Pharmaceuticals - Crunchbase Company Profile & Funding
Cognitive develops drug leads as a virtual company. Cognitive Pharmaceuticals was formed by Messer, Hoss, and others in 2001, based on a proprietary platform technology developed at the University of Toledo, College of Pharmacy. Cognitive Pharmaceuticals has completed a …See details»
Cognitive Pharmaceuticals - Overview, News & Similar companies ...
Who is Cognitive Pharmaceuticals. Cognitive Pharmaceuticals was established in 2001 based on a proprietary platform technology developed at the University of Toledo, College of PharSee details»
Cognitive Pharmaceuticals - PitchBook
Cognitive Pharmaceuticals is headquartered in Toledo, OH. What industry is Cognitive Pharmaceuticals in? Cognitive Pharmaceuticals’s primary industry is Pharmaceuticals. Is …See details»
Cognition Therapeutics, Inc.
CT1812, Cognition Therapeutics’ lead product candidate is a once-daily, oral, small-molecule designed to rescue trafficking deficits, a “housekeeping” function that is impaired in neurodegenerative and neuro-ophthalmic diseases.See details»
COGNITIVE PHARMACEUTICALS LTD - CAGE.report
COGNITIVE PHARMACEUTICALS LTD DUNS 045718900 / 04-571-8900. NCAGE Code: 414F7. COGNITIVE PHARMACEUTICALS LTD. CAGE Code: 414F7. COGNITIVE …See details»
Mithridion - Funding, Financials, Valuation & Investors - Crunchbase
Which types of acquisition does this organization make most frequently? Show . Acquiree Name . Announced Date . Price . Transaction Name . Cognitive Pharmaceuticals . Jun 5, 2008 — …See details»
COGNITIVE PHARMACEUTICALS, LTD - VentureRadar
Similar Companies: Precision Made Products, LLC. USA n/a n/a. IVIEW Therapeutics Inc USA n/a iView Therapeutics Inc. is a clinical stage biopharmaceutical company focused on the …See details»
Cognition Therapeutics - Crunchbase Company Profile & Funding
Cognition Therapeutics, Inc. is focused on the discovery and development of small molecule therapeutics targeting the toxic proteins that cause the cognitive decline associated with …See details»
Cognition Therapeutics - Overview, News & Similar companies
May 6, 2024 Explore Complete Organization Structure. ... Trial Demonstrates ~40% Mean Improvement in ADAS-Cog 11 vs Placebo and Consistent Positive Changes Across Multiple …See details»
How community pharmacists prioritize cognitive pharmaceutical
Introduction: There is broad consensus that community pharmacists should focus on the provision of pharmaceutical care. Studies, however, have shown that community pharmacists still spend …See details»
An in-depth examination of funded and unfunded cognitive …
Jun 10, 2017 Trends in cognitive pharmaceutical services being offered in community pharmacies and factors influencing provision. A notable expansion of services being provided …See details»
A tool for corporate decision making about cognitive …
Objective: To present and discuss the models, theories, ideas, and frameworks that corporate decision makers would apply to the implementation of cognitive pharmaceutical services. …See details»
Bosulif by Pfizer for Mild Cognitive Impairment: Likelihood of …
Bosulif is under clinical development by Pfizer and currently in Phase I for Mild Cognitive Impairment. According to GlobalData, Phase I drugs for Mild Cognitive Impairment does not …See details»
MW-151 by ImmunoChem Therapeutics for Cognitive Disorders: …
2 days ago MW-151 is under investigation for the treatment of cognitive disorder's. It is administered orally as capsule. It is a pyridazine derivative. It was also under development for …See details»
Cognitive enhancement by drugs in health and disease - PMC
In chronic mental disorders such as schizophrenia, cognitive deficits are a separable feature from positive (e.g. hallucinations and delusions) and negative (e.g. blunted affect, poverty of …See details»
AVN-322 by Avineuro Pharmaceuticals for Cognitive Disorders: …
2 days ago Avineuro’s pipeline products include AVN-211 for schizophrenia, AVN-322 for cognitive dysfunction, AVN-101 for anxiety disorders and others. The company develops …See details»
Brain Health Supplements Market Report Scope - Grand View …
The global brain health supplements market size was valued at USD 8.63 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 13.3% from 2023 to 2030. …See details»
Trends, challenges, and success factors in pharmaceutical portfolio ...
Oct 1, 2023 Insights from a globally facilitated survey of prevalent biases in portfolio-level decision-making in the pharmaceutical industry: 92 industry practitioners who work for globally …See details»
Azeliragon by Cantex Pharmaceuticals for Cognitive Impairment ...
2 days ago Cantex Pharmaceuticals overview. Cantex Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing novel, well-tolerated, oral treatments for …See details»
Damona Pharmaceuticals - Crunchbase Company Profile & Funding
Therapeutic compounds designed to bind and activate brain receptors to improve symptoms of memory loss and cognitive deficits caused by depression and aging. AC-101 A novel molecule …See details»